98319-26-7 Finasteride AKSci J10122
 
 
Loading Please Wait...
  J10122    AKSci Reference Standard
Finasteride
, >98% (HPLC)
 
N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide
N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide




IDENTITY
CAS Number:98319-26-7
MDL Number:MFCD00869737
MF:C23H36N2O2
MW:372.54
SPECIFICATIONS & PROPERTIES
Purity:>98% (HPLC)
Spectra:LCMS, HPLC
Physical Form:White to off-white powder
Melting Point:256-258°C
Long-Term Storage:Store at room temperature

BIOLOGICAL INFO
Solubility:DMSO: >20mg/mL; H2O: <1mg/mL; EtOH: 75mg/mL
Application(s):5-alpha Reductase inhibitor
Form:Free Base

REVIEW

 A specific inhibitor of steroid Type II 5-reductase, an intracellular enzyme that converts the androgen testosterone into 5-dihydrotestosterone (DHT). Finasteride is used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).

REFERENCES
[1]Kaplan SA, Lee JY, Meehan AG, Kusek JW; MTOPS Research Group (2011). Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 185(4):1369-73. PMID 21334655.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H302

Precautionary Statements
P264; P270; P301+P312; P330; P501


Current as of June 24, 2019

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

CATEGORIES

 APIs and Bioactives > Antiandrogens


PubChem